Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight

The mycosis fungoides market is projected to experience consistent growth from 2025 to 2034, fueled by increasing disease awareness, earlier detection, and the availability of established treatment ...
Business Wire

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and ...
Business Wire

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...
Seeking Alpha

Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s ...
ascopubs.org

Low-Dose Total Skin Electron Beam Radiotherapy in Stage IB-IIB Mycosis Fungoides: Results From the Prospective S-MISR Study

Low-dose radiation demonstrates efficacy in treating primary cutaneous T-cell lymphomas. This study evaluated the safety and efficacy of low-dose total skin electron beam therapy (TSEBT) regimens in ...

DelveInsight Business Research, LLP: Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight

The mycosis fungoides market is anticipated to progress steadily, influenced by the relatively small pipeline of emerging therapies. Leading candidates such as Soligenix's HYBRYTE and Innate ...